Clinical Research Directory

Inclusion Criteria: * Aged ≥ 18 years on the day of signing the ICF, male or female; * Eastern Cooperative Oncology Group (ECOG) performance status (PS) score: 0 or 1; * Measurable disease, per RECIST v1.1; * Adequate organ function; * Recover from all reversible AEs from previous anti-tumor treatment (i.e., Grade ≤ 1, according to NCI-CTCAE v5.0), excluding alopecia (any grade) and Grade ≤ 2 neuropathy peripheral, or who experience other abnormalities that are not clinically significant or toxicities judged to have no risk by the investigator; * Left ventricular ejection fraction (LVEF) ≥ 50%; Exclusion Criteria: * Previous treatment with drugs targeting CDH6 (including ADCs), or any drug containing topoisomerase I inhibitors (including ADCs); * Large and uncontrollable pleural, pericardial or abdominal effusion before the first dose (those who are stable for at least 2 weeks after drainage can be enrolled); * Progressive or symptomatic brain metastases; * Clinically significant bleeding symptoms or obvious bleeding tendency within 1 month before the first dose * History of significant cardiac disease, or poorly controlled diabetes mellitus; * History of recurrent autoimmune diseases; * History of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML); * History of other active malignant tumors within 3 years before signing the informed consent form; * If female, is pregnant or breastfeeding; * Be allergic to any component of QLS5133 or its excipients.